Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Inclusion Criteria: * Male or female subjects, aged 18 years and older * Any of the following: * Known or suspected supra-aortic arterial disease based on: * Prior stroke * Transient ischemic attack (TIA) * Amaurosis Fugax (transient monocular blindness) * Referred for evaluation of any supra-aortic vessel (for clinically significant stenosis) * Follow-up for a stent in a supra-aortic vessel * Prior imaging study (CTA or ultrasound) showing ≥ 50% stenosis of a supra-aortic vessel segment (within 60 days before consent). The proportion of subjects with positive disease (determined by the investigator, based on CTA or ultrasound) will be monitored during the study, and enrolment may be further restricted to require ≥ 70% stenosis to ensure that overall there are an adequate number of subjects with clinically significant disease for the evaluation of study endpoints. * Willingness to undergo the routine Contrast Enhanced Magnetic Resonance Angiography \[CE MRA\] examination with gadobutrol * Willingness and ability to follow directions and complete all study procedures specified in the protocol * Females of childbearing potential only: Negative pregnancy test on the day of the MRA before the administration of study drug Exclusion Criteria: * Pregnant or nursing (including pumping for storage and feeding) * Received any other investigational product or participation in any other clinical trial within 30 days before enrollment into this study * Previous en…